A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Richard D. Press(Oregon Health & Science University), Michael W. Deininger(Versiti Blood Center of Wisconsin), Rui Yang(Tianjin University of Science and Technology), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Brian Druker(Oregon Health & Science University), Chad Galderisi(Center for Cancer and Blood Disorders), Stephanie G. Willis(Cancer Institute (WIA)), Carole Rempfer(Center for Cancer and Blood Disorders)
Cited by 123
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464